April 28, 2021Open Access

Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD

Key Points

Key points are not available for this paper at this time.

Abstract

Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not the prespecified noninferiority criterion for cardiovascular safety in patients with NDD-CKD. (Funded by Akebia Therapeutics and Otsuka Pharmaceutical; PRO2TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Glenn M. Chertow

Pablo E. Pérgola

Youssef M.K. Farag

Journals

New England Journal of Medicine

Actions

Institutions

Stanford University

Johns Hopkins University

Emory University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study